Applied Molecular Transport (NASDAQ:AMTI) Shares Gap Down to $44.99

Shares of Applied Molecular Transport Inc. (NASDAQ:AMTI) gapped down prior to trading on Friday . The stock had previously closed at $44.99, but opened at $43.97. Applied Molecular Transport shares last traded at $44.08, with a volume of 158 shares traded.

A number of equities analysts recently issued reports on AMTI shares. Jefferies Financial Group raised their target price on Applied Molecular Transport from $38.00 to $75.00 in a research note on Tuesday, March 23rd. SVB Leerink lifted their target price on shares of Applied Molecular Transport from $32.00 to $74.00 and gave the company an “outperform” rating in a report on Thursday, February 25th. JMP Securities assumed coverage on Applied Molecular Transport in a research report on Wednesday, March 17th. They set an “outperform” rating and a $92.00 target price on the stock. Finally, Zacks Investment Research raised Applied Molecular Transport from a “sell” rating to a “hold” rating in a research note on Tuesday, May 25th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $68.75.

The firm has a market cap of $1.70 billion and a P/E ratio of -17.64. The stock’s fifty day moving average price is $47.73.

Applied Molecular Transport (NASDAQ:AMTI) last released its quarterly earnings data on Wednesday, May 12th. The company reported ($0.58) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.75) by $0.17. Sell-side analysts forecast that Applied Molecular Transport Inc. will post -2.52 earnings per share for the current fiscal year.

In other Applied Molecular Transport news, Director David Lamond purchased 25,000 shares of Applied Molecular Transport stock in a transaction dated Tuesday, April 6th. The shares were acquired at an average price of $42.00 per share, with a total value of $1,050,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Bittoo Kanwar sold 7,500 shares of the firm’s stock in a transaction that occurred on Wednesday, April 7th. The shares were sold at an average price of $54.79, for a total transaction of $410,925.00. Following the completion of the transaction, the insider now directly owns 7,500 shares of the company’s stock, valued at approximately $410,925. The disclosure for this sale can be found here. Corporate insiders own 26.70% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in AMTI. Royal Bank of Canada increased its stake in shares of Applied Molecular Transport by 5,390.3% during the first quarter. Royal Bank of Canada now owns 1,702 shares of the company’s stock worth $75,000 after buying an additional 1,671 shares during the period. Citigroup Inc. grew its stake in shares of Applied Molecular Transport by 511.2% during the fourth quarter. Citigroup Inc. now owns 3,643 shares of the company’s stock worth $112,000 after purchasing an additional 3,047 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Applied Molecular Transport by 33.4% in the fourth quarter. JPMorgan Chase & Co. now owns 6,177 shares of the company’s stock valued at $190,000 after buying an additional 1,548 shares in the last quarter. Laurion Capital Management LP purchased a new stake in Applied Molecular Transport during the 1st quarter worth about $220,000. Finally, Principal Financial Group Inc. acquired a new position in shares of Applied Molecular Transport during the 4th quarter worth about $221,000. Institutional investors and hedge funds own 63.38% of the company’s stock.

Applied Molecular Transport Company Profile (NASDAQ:AMTI)

Applied Molecular Transport Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications.

Featured Story: What is a Roth IRA?

Receive News & Ratings for Applied Molecular Transport Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Molecular Transport and related companies with MarketBeat.com's FREE daily email newsletter.